Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2011

View Archived Issues

Monash University develops dual-action PILs for fast delivery of active pharmaceutical ingredients

New hepcidin inhibitor exhibits antianemic effects in vivo

Phase II ARRY-520 trial in multiple myeloma yields encouraging results

Phase I study evaluates SCH-900776/cytarabine combination for leukemia

Oral rigosertib shows promise as a therapy for myelodysplastic syndrome

Asahi Kasei integrates two core operating companies

Celldex completes accrual in CDX-011 study

Astellas Pharma and UMN Pharma report phase I/II data on seasonal flu vaccine

Merck & Co. patents new hPDK1 inhibitors

Novel farnesyl pyrophosphate synthase inhibitors discovered in Canada

Janssen Pharmaceutica discloses novel estrogen-related receptor-alpha ligands

Enrollment begins in phase III trial of CF-101

NIAID begins trial of experimental chikungunya fever vaccine

Exelixis grants program license to Merck & Co.

Belgium-based company first to advance fatty acid FFA2 receptor antagonist to clinic

Novel fused imidazole derivatives prepared by Toa Eiyo

Abbott synthesizes new voltage-gated Ca(V)2.2 calcium channel antagonists

First patient with metastasized colorectal cancer treated in phase II trial of armed oncolytic virus

Phage Pharmaceuticals submits IND for first-in-class therapeutic

CytRx launches phase IIb study in advanced soft tissue sarcoma

Chelsea Therapeutics announces new data on droxidopa in fibromyalgia

Valeant Pharmaceuticals completes acquisition

Santarus files NDA for budesonide tablets

Trial of new patch for osteoporosis meets endpoints

XOMA commences new study of gevokizumab

MorphoSys commences clinical testing of MOR-103 for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...